Bernard Landry

3.0k total citations · 1 hit paper
16 papers, 1.2k citations indexed

About

Bernard Landry is a scholar working on Infectious Diseases, Immunology and Epidemiology. According to data from OpenAlex, Bernard Landry has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 10 papers in Immunology and 9 papers in Epidemiology. Recurrent topics in Bernard Landry's work include Tuberculosis Research and Epidemiology (12 papers), Immunodeficiency and Autoimmune Disorders (7 papers) and Immune responses and vaccinations (4 papers). Bernard Landry is often cited by papers focused on Tuberculosis Research and Epidemiology (12 papers), Immunodeficiency and Autoimmune Disorders (7 papers) and Immune responses and vaccinations (4 papers). Bernard Landry collaborates with scholars based in United Kingdom, United States and South Africa. Bernard Landry's co-authors include J. Bruce McClain, Helen McShane, Hassan Mahomed, Thomas J. Scriba, Michèle Tameris, Willem A. Hanekom, Mark Hatherill, Gregory Hussey, Stephen Lockhart and Margaret Ann Snowden and has published in prestigious journals such as The Lancet, Blood and The Journal of Immunology.

In The Last Decade

Bernard Landry

15 papers receiving 1.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

2013 753 citations Michèle Tameris, Mark Hatherill et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernard Landry United Kingdom	11	963	712	556	199	145	16	1.2k
Sebastian Gelderbloem South Africa	14	1.2k 1.3×	1.1k 1.6×	683 1.2×	203 1.0×	209 1.4×	17	1.7k
Andreia Soares South Africa	15	723 0.8×	745 1.0×	404 0.7×	129 0.6×	110 0.8×	19	1.1k
Azra Blazevic United States	13	524 0.5×	845 1.2×	507 0.9×	156 0.8×	69 0.5×	26	1.2k
Rosemary E. Weir United Kingdom	18	824 0.9×	736 1.0×	471 0.8×	111 0.6×	142 1.0×	26	1.2k
Joanna R. Kirman New Zealand	22	533 0.6×	992 1.4×	490 0.9×	194 1.0×	112 0.8×	39	1.5k
Iman Satti United Kingdom	21	741 0.8×	634 0.9×	427 0.8×	172 0.9×	57 0.4×	43	1.1k
Marcela Parra United States	15	696 0.7×	343 0.5×	544 1.0×	266 1.3×	121 0.8×	25	1.2k
Margaret Ann Snowden South Africa	5	676 0.7×	520 0.7×	348 0.6×	145 0.7×	85 0.6×	6	824
Wendy Wieland‐Alter United States	19	675 0.7×	328 0.5×	361 0.6×	165 0.8×	58 0.4×	35	1.1k
Joshua S. Woodworth United States	19	960 1.0×	873 1.2×	599 1.1×	330 1.7×	111 0.8×	22	1.4k

Countries citing papers authored by Bernard Landry

Since Specialization

Citations

This map shows the geographic impact of Bernard Landry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Landry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Landry more than expected).

Fields of papers citing papers by Bernard Landry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Landry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Landry. The network helps show where Bernard Landry may publish in the future.

Co-authorship network of co-authors of Bernard Landry

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Landry. A scholar is included among the top collaborators of Bernard Landry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Landry. Bernard Landry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Abd‐Elrahman, Amr, Bernard Landry, Alexander W. Levis, et al.. (2025). Counterspeech encouraging users to adopt the perspective of minority groups reduces hate speech and its amplification on social media. Scientific Reports. 15(1). 22018–22018.

2.

Andrews, Jason R., Elisa Nemes, Michèle Tameris, et al.. (2017). Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. The Lancet Respiratory Medicine. 5(4). 282–290. 95 indexed citations

3.

Reyn, C. Fordham von, Timothy Lahey, Robert D. Arbeit, et al.. (2017). Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. PLoS ONE. 12(5). e0175215–e0175215. 51 indexed citations

4.

Luabeya, Angelique Kany Kany, Michèle Tameris, Hennie Geldenhuys, et al.. (2017). Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. The International Journal of Tuberculosis and Lung Disease. 21(7). 778–783. 5 indexed citations

5.

Luabeya, Angelique Kany Kany, Michèle Tameris, Hennie Geldenhuys, et al.. (2015). Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. The Pediatric Infectious Disease Journal. 34(11). 1218–1222. 7 indexed citations

6.

Mulenga, Humphrey, Michèle Tameris, Angelique Kany Kany Luabeya, et al.. (2015). The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children. The Pediatric Infectious Disease Journal. 34(11). 1157–1162. 18 indexed citations

7.

Sheehan, Sharon R., Stephanie A. Harris, Iman Satti, et al.. (2015). A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. PLoS ONE. 10(11). e0141687–e0141687. 28 indexed citations

8.

Churchyard, Gavin, Margaret Ann Snowden, David A. Hokey, et al.. (2015). The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3. Vaccine. 33(15). 1890–1896. 24 indexed citations

9.

Hokey, David A., Dawn M. O’Dee, Andrew J. Graves, et al.. (2014). Heterologous prime-boost with Ad35/AERAS-402 and MVA85A elicits potent CD8+ T cell immune responses in a phase I clinical trial (VAC7P.969). The Journal of Immunology. 192(Supplement_1). 141.14–141.14. 4 indexed citations

10.

Tameris, Michèle, Mark Hatherill, Bernard Landry, et al.. (2013). Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. The Lancet. 381(9871). 1021–1028. 753 indexed citations breakdown →

11.

Tameris, Michèle, Helen McShane, J. Bruce McClain, et al.. (2013). Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis. 93(2). 143–149. 30 indexed citations

12.

Hoft, Daniel F., Azra Blazevic, Bernard Landry, et al.. (2012). A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine. 30(12). 2098–2108. 65 indexed citations

13.

Null, Donald M., Bernard Pollara, Penelope H. Dennehy, et al.. (2005). SAFETY AND IMMUNOGENICITY OF PALIVIZUMAB (SYNAGIS) ADMINISTERED FOR TWO SEASONS. The Pediatric Infectious Disease Journal. 24(11). 1021–1023. 26 indexed citations

14.

Hafner, Richard, James Bethel, Maureen Power, et al.. (1998). Tolerance and Pharmacokinetic Interactions of Rifabutin and Clarithromycin in Human Immunodeficiency Virus-Infected Volunteers. Antimicrobial Agents and Chemotherapy. 42(3). 631–639. 65 indexed citations

15.

Lieberman, Judy, Paul R. Skolnik, G R Parkerson, et al.. (1997). Safety of Autologous, Ex Vivo-Expanded Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Infusion in HIV-Infected Patients. Blood. 90(6). 2196–2206. 72 indexed citations

16.

Lieberman, Judy, Paul R. Skolnik, G R Parkerson, et al.. (1997). Safety of Autologous, Ex Vivo-Expanded Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Infusion in HIV-Infected Patients. Blood. 90(6). 2196–2206. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact